This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Veeva Rolls Out Nitro to Unify Healthcare Industry Data
by Zacks Equity Research
Veeva (VEEV) strengthens its position by providing the life sciences industry with a streamlined commercial database besides notable technological innovations.
Why Athenahealth (ATHN) Is a Major Medtech Acquisition Target
by Ryan McQueeney
On today's episode of the Tech Talk Tuesday podcast, Ryan McQueeney discusses Athenahealth (ATHN), a medical technology company that has found itself the target of an activist takeover from Paul Singer's Elliott Management.
Why Did Athenahealth (ATHN) Stock Soar Today?
by Ryan McQueeney
Shares of Athenahealth (ATHN) opened more than 20% higher on Monday after Paul Singer's Elliott Management offered to buy the healthcare technology company in an all-cash deal valued at $160 per share.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.
Can Business Services Aid athenahealth's (ATHN) Q1 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.
Haemonetics Rides High on Plasma, Blood Center Remains Weak
by Zacks Equity Research
We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.
GNC Holdings Partners Rapid Nutrition, Forays in Australia
by Zacks Equity Research
GNC Holdings' (GNC) tie-up with Rapid Nutrition is likely to fuel the company's entry and expansion into the Australian healthcare market.
Supply Delay Hits Zimmer Biomet, Operational Plan Buoys Hope
by Zacks Equity Research
Zimmer Biomet's (ZBH) dull Knee sales continue to bother due to slower pace of supply recovery and sales recapture of certain key brands.
Hill-Rom Banks on Product Innovation, Strategic Buyouts
by Zacks Equity Research
Hill-Rom (HRC) sets sights on product innovation, the latest launch being Connex Cardio ECG. The company also revises its 2020 financial aims and outlook, backed by new tax reform-related benefits.
Cerner's EHR to Aid Kern Medical's Population Management
by Zacks Equity Research
Cerner's (CERN) coveted Millennium and HelatheIntent EHR platforms to overhaul Kern Medical's array of services.
Medtronic to Grow on Strong Fundamentals, High Costs a Woe
by Zacks Equity Research
Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022
Align Unveils Vivera Retainers for Deep Bite Correction
by Zacks Equity Research
Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.
Align Technology Broadens Invisalign Suite, Extends Reach
by Zacks Equity Research
Align Technology (ALGN) leaves no stone unturned to boost the Invisalign product portfolio and strengthen its hold in the high-potential invisible orthodontics market.
ABIOMED's (ABMD) Impella 5.5 Receives CE Mark in Europe
by Zacks Equity Research
ABIOMED's (ABMD) Impella line consistently boosts earnings in and outside the United States. Its Impella 5.5 successfully treats first patient at University Heart Center, Hamburg.
MedTech Takes to Big Data Analytics: 3 Stocks Catch Eye
by Nabaparna Bhattacharya
Here we take a look at the major factors that are driving the importance of big data in the MedTech space.
Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan
by Zacks Equity Research
Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.
Masimo (MASI) Launches UniView, Improves Patient Safety
by Zacks Equity Research
Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.
Here's Why You Should Invest in ABIOMED (ABMD) Right Now
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella holds promise. A raised guidance encourages.
Cooper (COO) Buys LifeGlobal to Widen Fertility Device Line
by Zacks Equity Research
Cooper Companies' (COO) LifeGlobal asset purchase is likely to boost CooperSurgical.
Here's Why You Should Invest in Surmodics (SRDX) Right Now
by Zacks Equity Research
Surmodics (SRDX) continues to benefit from solid growth in the In Vitro Diagnostics (IVD) segment.
Boston Scientific to Acquire Securus Medical, Boost EP Unit
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
Zacks.com highlights: athenahealth, Applied Materials, Pioneer Natural Resources and TriNet Group
by Zacks Equity Research
Zacks.com highlights: athenahealth, Applied Materials, Pioneer Natural Resources and TriNet Group
FDA Nod for Abiomed Impella CP with SmartAssist Widens Suite
by Zacks Equity Research
Abiomed (ABMD) continues with the slew of developments to boost its flagship, Impella product line.
IRCCO Picks Cerner's HealtheIntent for Patients of Illinois
by Zacks Equity Research
Cerner's (CERN) HealtheIntent intends to serve 20,000 Medicare patients in Illinois through IRCCO's accountable care organizations.
AngioDynamics (ANGO) Product Line Strong, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.